Optic neuroretinitis in association with BCNU and procarbazine therapy.
A 53-year-old man with multiple myeloma and plasma cell luekemia developed severe, acute bilateral optic neuroretinitis 8 days after chemotherapy with BCNU, procarbazine, cyclophosphamide, and prednisolone. He showed some return of function over the following 6 weeks before his death. Both BCNU and procarbazine are known to cross the blood--brain barrier. Procarbazine is known to interfere with neurological function. BCNU has been reported to transiently interfere with vision and, although this patient had highly morbid disease, the onset of optic neuroretinitis 8 days after combination therapy with these 2 drugs raises the possibility that one or both in combination may have been the cause of the optic neuropathy.
D002330:Carmustine / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007952:Leukemia, Plasma Cell / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D009902:Optic Neuritis / Q000139:chemically induced*; D011344:Procarbazine / Q000009:adverse effects*; D012173:Retinitis / Q000139:chemically induced*; D013997:Time Factors
D011344:Procarbazine; D002330:Carmustine